Introduction {#Sec1}
============

Chronic hepatitis B (CHB) is a major global health challenge and a leading cause of liver-related morbidity and mortality within the Asia-Pacific region. To help guide clinicians in their management of patients with CHB, several regional and country expert associations have developed treatment guidelines, incorporating advances in both the understanding of the natural history of the disease and the expanding range of therapeutic options \[[@CR1]--[@CR4]\]. Despite the availability of a large amount of new data on CHB treatment, many issues remain unresolved \[[@CR1], [@CR5]\]. In November 2008, 12 experts from the Asia-Pacific region formed the *Asia-Pacific Panel Recommendations for the Optimal Management of Chronic Hepatitis B* (APPROACH) Working Group in an attempt to address issues of "whom to treat and for how long?" The group met at the Beijing Ditan Hospital, China, where relevant data from recent studies were reviewed, assessed, and challenged, with the significance of and controversy about reported findings discussed and debated.

This paper aims to identify the challenges facing current guidelines and discuss propositions for future CHB guideline amendments, with the hope of enhancing antiviral treatment in the region.

Natural history of hepatitis B virus {#Sec2}
------------------------------------

The hepatitis B virus (HBV) causes chronic infection in 350--400 million people worldwide, 75% of whom are in the Asia-Pacific region, with the majority acquiring the infection at birth, or within the first 1--2 years of life \[[@CR6], [@CR7]\]. HBV is a known human carcinogen \[[@CR8]--[@CR10]\], with research indicating it as a strong risk factor for cirrhosis and hepatocellular carcinoma (HCC) \[[@CR11], [@CR12]\].

Three large-scale, long-term, prospective studies looking at cohorts from Hong Kong \[[@CR13]\], China \[[@CR14]\], and Taiwan \[[@CR15]\] assessed the incidence of and risk factors for cirrhosis, HCC, and death from liver disease among CHB patients. Cohorts each included more than 1,000 subjects and were followed for 7--11 years. All three studies came to similar conclusions: HBV DNA concentration is the most important predictor of HCC; the higher the HBV DNA load, the higher the incidence of HCC. These findings, along with data from similar risk prediction studies \[[@CR16]\], have led to all major treatment guidelines advocating the elimination of viral replication as the primary aim of CHB treatment \[[@CR17]\].

HBV genotype has also been identified to be possibly associated with an increased risk of HCC development \[[@CR18], [@CR19]\]. Important differences exist among HBV genotypes and subgenotypes, which display different clinical and virological characteristics \[[@CR20], [@CR21]\]. Such differences may affect the natural history and overall progression of the disease, as well as response to treatment.

Genotypes B and C are predominant in Asia, characteristically acquired through vertical transmission in the perinatal period. They are distinct from HBV genotypes A and D, acquired primarily in adulthood and predominant in Western patients \[[@CR18], [@CR22]\]. There is increasing evidence that HBV genotype C is associated with more severe liver disease and an increased risk of HCC than HBV genotype B \[[@CR6], [@CR19]\].

Despite these prognostic implications, HBV genotype has no substantial impact on the therapeutic response to oral nucleoside or nucleotide analogs \[[@CR23], [@CR24]\]. Further studies are needed to understand the implications of HBV genotype, and of particular interest is the need to adopt different treatment initiation and cessation criteria for patients with different genotypes and/or subgenotypes \[[@CR13]\]. In addition, studies to address the role of some common HBV variants in the development of HCC, such as pre-S deletions and T1653 mutations, are warranted \[[@CR25], [@CR26]\].

Treatment initiation: "whom to treat?" {#Sec3}
======================================

The decision to commence treatment must balance the likelihood of a sustained treatment response, with the future risk of liver-related morbidity and mortality. Consideration of further factors, including patient age, concurrent illness, medication compliance, liver disease activity, likelihood of long-term benefit, and potential therapeutic risks such as side effects, must be included as part of a risk--benefit analysis \[[@CR27]\]. Cost, drug availability, and the emergence of antiviral resistance are important considerations of particular interest to the Asia-Pacific region.

A large amount of new data have become available in recent years, suggesting that conventional criteria for treatment initiation based on existing disease progression do not necessarily correlate with the future risk of disease complications. There is therefore a need for a fresh appraisal of the current evidence, with subsequent revisions and updates for future guidelines.

Challenges and unresolved issues {#Sec4}
--------------------------------

Indications for treatment initiation are currently based on three criteria: serum aminotransferase (alanine, ALT; aspartate; AST) levels; serum HBV DNA levels; and histological grade and stage.

### Serum ALT level {#Sec5}

Current Asian Pacific Association for the Study of the Liver (APASL) recommendations indicate that treatment initiation should be considered in patients with active HBV replication and ALT levels at least twice the upper limit of normal (ULN), but not in patients with persistently normal or minimally elevated ALT levels, except where there is evidence of advanced fibrosis or cirrhosis \[[@CR1]\]. Such recommendations are based on the observation that the latter subjects usually experience minimal histological changes and respond poorly in terms of HBeAg seroconversion rate to interferon (IFN) and oral antiviral therapy \[[@CR1], [@CR12]\]. Emerging data from several clinical studies indicate that significant liver damage can occur in patients with high viral loads and persistently normal ALT levels, particularly if they are HBeAg negative \[[@CR28], [@CR29]\]. These patients are easily excluded from treatment as a result of current ALT-dependent treatment initiation criteria, particularly when liver biopsy is not feasible.

ALT is now thought to be a relatively inaccurate marker of liver fibrosis and may be a better indicator for necroinflammation, correlating poorly with the degree of liver disease, particularly when only single measurements are available. Recent studies suggest that patients with normal serum ALT levels have no or minimal disease progression \[[@CR30], [@CR31]\], whereas a substantial proportion of Asian patients with minimally elevated ALT levels have significant histological disease \[[@CR28]\]. Another study reported that 23.7% of Asian patients with persistently normal ALT levels had significant histological findings including inflammation and fibrosis \[[@CR32]\]. Further studies indicate that a single, high-normal ALT reading (between 0.5 and 1 times the ULN) indicates a risk of advanced fibrosis in both HBeAg-positive and HBeAg-negative patients \[[@CR33]--[@CR35]\]. In a Hong Kong longitudinal follow-up study, the cumulative risk of disease complications, stratified according to ALT levels on presentation, was found to be highest in patients with ALT levels between one and two times the ULN. Patients with ALT levels between 0.5 and 1 times the ULN also had a significantly increased risk of complications \[[@CR16]\], a claim supported by a Korean population study \[[@CR36]\].

Another concern of the inaccuracy of ALT as a marker for liver fibrosis is the suitability of an ULN "threshold" due to variability in quoted reference ranges and heterogeneity within target populations. Several variables often not accounted for when determining the "normal" ALT range include age, fasting blood glucose, and serum triglyceride levels, as well as differences in the commercial assays used and the reference populations chosen by each manufacturer to establish its reference range \[[@CR37]\]. ALT levels have further been shown to vary according to body mass index (BMI). One study proposed that the current ULN may be set too high, with values close to the abnormal ULN value for someone with a low BMI \[[@CR38]\]. Indirect evidence for this comes from cohort studies of healthy patients, which indicated that the ULN should be 30 IU/mL for men and 19 IU/mL for women \[[@CR37], [@CR39]\]. Existing regional guidelines do not specify ULN values for serum ALT, but APASL suggests "high normal" (ALT 0.5--1 times ULN) and "low normal" (ALT ≤0.5 times ULN) to help differentiate ULN values for serum ALT. As ALT ULN varies greatly from laboratory to laboratory, ranging from 36 U/L \[[@CR40]\] to 60 U/L \[[@CR41]\] in published studies, standardization may not be appropriate. For borderline ALT levels, alternative indicators such as liver biopsy and histology are needed to evaluate the extent of liver damage.

In light of these data, the most recent European Association for the Study of the Liver (EASL) treatment guidelines suggest that abnormal ALT levels together with HBV DNA levels of more than 2,000 IU/mL are sufficient criteria for treatment commencement. A liver biopsy is further recommended for determining the degree of necroinflammation and fibrosis in such patients \[[@CR3]\].

### Serum HBV DNA level {#Sec6}

Quantitation of serum HBV DNA previously utilized an arbitrarily assigned value of 10^5^ copies/mL as a criterion for CHB treatment, based on a previous understanding of CHB natural history, and lower sensitivity of previously available viral load quantification assays \[[@CR42]\]. HBV DNA levels are currently quantified by polymerase chain reaction (PCR) assays, which can detect HBV DNA levels as low as 100 copies/mL.

In the most recent APASL update, HBV DNA levels in excess of 20,000 IU/mL (or 100,000 copies/mL) and 2,000 IU/mL (or 10,000 copies/mL), together with ALT levels more than two times the ULN, have been proposed as thresholds for treatment of HBeAg-positive and HBeAg-negative hepatitis, respectively. While such HBV DNA thresholds identify the majority of patients with active liver disease, more than 10% of HBeAg-negative CHB patients with persistently or transiently increased serum ALT levels may have serum HBV DNA levels that fall below the recommended cutoff of 2,000 IU/mL \[[@CR43]\]. In fact, no single HBV DNA level can confidently differentiate patients with active or inactive liver disease after HBeAg seroconversion \[[@CR44], [@CR45]\]. Furthermore, a significant proportion of Asian patients are at continued risk of liver complications despite their HBV DNA levels falling below 10,000 copies/mL \[[@CR7], [@CR46]\]. Patients with HBV DNA levels below 2,000 IU/mL are also at a significantly higher risk of developing HCC than uninfected patients \[[@CR47]\]. Such studies reinforce the impact of unsuppressed viral load on disease progression and suggest that treatment initiation may need to be considered in patients with lower levels of HBV DNA, especially among patients with advanced fibrosis who have a significant risk of developing HCC \[[@CR48]\].

### Histological grade {#Sec7}

Current guidelines recommend liver biopsy to assess the degree of necroinflammation and liver fibrosis prior to treatment initiation in patients with increased HBV DNA and/or minimally elevated ALT levels (1--2 times the ULN). Liver biopsy is also recommended for patients older than 40 years, especially those with "high normal" ALT levels \[[@CR1]\]. Although liver biopsy remains the gold standard for assessing hepatic fibrosis, its use has several limitations including sampling error and intra- or interobserver sampling variability \[[@CR3], [@CR49], [@CR50]\]. Inadequate liver biopsy may further pose misleading histological information that precludes cirrhotic patients from antiviral treatment \[[@CR48]\]. In addition, although the risk of severe complications is very low (1 in 4,000--10,000), liver biopsy is associated with undesirable procedural risks such as bleeding. Patients potentially opt to avoid such invasive procedures, so there is a need for a simple, reliable, noninvasive alternative, either complementing or eliminating liver biopsy altogether \[[@CR3], [@CR51]\].

APPROACH Working Group consensus {#Sec8}
--------------------------------

Current treatment initiation criteria potentially exclude patients with a high risk of disease progression, particularly patients with increased viral load and normal or minimally elevated ALT levels who are probably not in the immune-tolerant phase (i.e., \>40 years of age). Serum ALT, as one of the key conventional treatment initiation criteria, does not satisfactorily reflect existing liver damage sensitively or specifically and is a weaker risk factor than viral load in predicting future liver disease complications. While the current APASL recommended monitoring approach toward immune-tolerant patients remains suitable, new methods are needed to evaluate liver histology in the setting of normal ALT and high HBV DNA levels. Future CHB treatment initiation recommendations should be based on the primary treatment objective of preventing liver injury, which may be achievable by treating before complications arise, in the majority of patients.

### Special populations {#Sec9}

Decompensated patients must be treated as soon as possible, as should be patients with persistent disease activity, signified by elevated ALT levels, and abnormal liver function. Decompensated cirrhotic patients with detectable HBV DNA by PCR should also be treated as early as possible \[[@CR2]--[@CR4]\]. Patients with histological evidence of liver damage as indicated by liver biopsy should be treated. Asymptomatic patients with persistently low ALT levels (normal or minimally elevated) and lack of clinical evidence of liver damage (due to refusal of liver biopsy) may also be treated, depending on the likelihood of disease progression after consideration of additional risk factors including age, gender, and family history of HCC.

### Use of diagnostic tools {#Sec10}

Evaluation of existing liver damage can be established histologically using liver biopsy; however, further research into the applicability of noninvasive tests in various HBV patient populations is of particular interest. Several formulae based on direct and indirect serum markers of hepatic fibrosis focusing on chronic hepatitis C (CHC) have been developed and evaluated \[[@CR52]\] but may not be suitable for CHB patients \[[@CR53], [@CR54]\]. Noninvasive predictive models developed for CHB patients need further validation by other groups \[[@CR55]--[@CR57]\].

Transient elastography, a diagnostic tool that has recently been introduced as a novel, rapid, noninvasive, and reproducible method to measure liver stiffness, is also of interest. Meta-analyses of studies involving predominantly CHC patients have confirmed a high accuracy of liver stiffness measurements (LSM) in predicting advanced hepatic fibrosis and cirrhosis \[[@CR58], [@CR59]\]. The technique has also been validated against histology in several studies including CHB patients \[[@CR60]--[@CR62]\]. Despite the advantages of this technique, its accuracy is inversely related to age and BMI, with LSM failures reported in overweight patients with a BMI of more than 28 \[[@CR63], [@CR64]\]. In addition, major changes in the inflammatory biochemical activity of serum transaminases, induced by liver disease, may affect LSM results \[[@CR65]\]. Measurements of liver stiffness are also technically difficult in particular individuals, including patients with ascites and large vessels and patients with a narrow intercostal space \[[@CR51]\].

### Predictors of disease progression {#Sec11}

Future recommendations are needed to promote the adoption of comprehensive assessments for clearly defined common viral replication and liver function parameters, prior to treatment initiation, and at various points during treatment to determine efficacy. Assessments should primarily consist of easily accessible tests including but not limited to HBV DNA level, complete blood counts, prothrombin time, biochemical tests, including AST and ALT, γ-glutamyl transpeptidase, alkaline phosphatase, and serum albumin, and hepatic ultrasonography \[[@CR1], [@CR3]\]. Additional testing for further parameters that are not easily accessible, or affordable, such as HBV genotype, and precore and basal core promoter mutations should be supplementary until their role has been properly defined.

Estimation of the risk of disease progression might be possible through the use of a "risk calculator" based on common viral and liver parameters, as demonstrated in other disease areas, including cardiovascular disease and breast cancer \[[@CR66], [@CR67]\]. Several independent groups have developed different risk prediction tools based on population or hospital patient natural history cohorts to evaluate the risk of disease progression \[[@CR11], [@CR13], [@CR15], [@CR16], [@CR18], [@CR68]\]. These tools include treatment assessment algorithms, within which all potential risk factors, including gender, age, HBeAg status, ALT elevation, cirrhosis status, HBV genotype, and HBV DNA level, are incorporated. Scoring systems translate these factors into risk scores that can be further incorporated into risk function nomograms, offering a means of making a fast, reasonable, and visually explicit estimation of HCC risk \[[@CR6], [@CR69]\]. Such a "risk calculator" tool may help identify patients most benefiting from immediate treatment intervention (e.g., a 40-year-old individual with an 80% risk of HCC development in the next 5 years), thereby supporting the objective to treat as early as possible. This tool may also be particularly useful in patients with asymptomatic disease.

A modified treatment paradigm to improve on current patient risk stratification criteria is also important. In addition, further representative studies for the validation of risk calculation models as they evolve are needed and may, in turn, inform the deciding cutoff levels for treatment initiation in specific patient populations. Finally, there is a requirement for future prospective studies to evaluate antiviral treatment outcomes and likelihood of long-term benefit of therapeutic intervention in specific patient populations, particularly those in the immune-tolerant phase.

Treatment duration: "for how long?" {#Sec12}
===================================

Treatment duration is dictated by the desired treatment goal, the ideal long-term goal of CHB therapy being the complete suppression of HBV replication, leading to improved quality of life and survival by preventing disease progression, HCC, and death \[[@CR3], [@CR12], [@CR70]\]. HBsAg seroclearance, indicating resolution of chronic infection, is the optimal measure of treatment success but is rarely achieved, even with pegylated IFN therapy. Approximately 0.5% of HBsAg carriers will clear HBsAg yearly; most will develop anti-HBs \[[@CR2]\]. Similarly, for nucleos(t)ide analogs, only a small proportion of patients can achieve HBsAg seroclearance. Most can achieve only viral suppression, with virological rebound typically occurring upon treatment cessation \[[@CR71], [@CR72]\]. Therefore, the issue whether treatment with nucleos(t)ide analogs should be stopped remains controversial.

Challenges and unresolved issues {#Sec13}
--------------------------------

Three conventional targets of antiviral therapy are addressed within treatment guidelines: sustained undetectable HBV DNA levels by PCR; normalization of ALT levels; and HBeAg seroconversion. More recently, recommendations have incorporated HBsAg seroclearance as an end point for treatment cessation \[[@CR3]\].

### HBeAg seroconversion and HBeAg-positive patients {#Sec14}

Current APASL guidelines state that oral antiviral treatment cessation can be considered in HBeAg-positive patients with HBeAg seroconversion and undetectable HBV DNA levels on two consecutive occasions, with at least 6-month intervals \[[@CR1]\]. This is likely based on studies that reported that 66.8 and 85% of spontaneous seroconverters showed sustained remission \[[@CR35], [@CR41]\]. Among HBeAg seroconverters, a certain proportion may have a sustained response with relapse rates of 27% reported, shrinking to 11% in patients who had pretreatment HBV DNA levels of 10^8^ copies/mL or less \[[@CR73]\]. However, HBeAg seroconversion alone does not always signify a sustained treatment response. While it has been suggested that HBeAg positivity is associated with an increased risk of HCC \[[@CR74]\], more than 70% of patients with complications of cirrhosis and HCC are HBeAg-negative \[[@CR16]\]. Finally, an earlier histological study showed no significant difference in the incidence of cirrhosis in HBeAg-positive patients when compared with anti-HBe positive patients \[[@CR75]\].

Relapse following oral antiviral therapy is also frequent in HBeAg-seroconverted patients. A Taiwanese study on the cumulative development of HBeAg-negative CHB after spontaneous HBeAg seroconversion found that the rate was highest in the first few years following seroconversion, reaching a plateau rate of 25% after approximately 10 years \[[@CR41]\]. In a further follow-up study, reactivation of hepatitis following treatment-induced seroconversion was higher (45% of patients) and earlier than that of spontaneous seroconversion (30% of patients) \[[@CR76]\]. The majority of Korean patients are infected with HBV genotype C, which is associated with high relapse levels following lamivudine therapy \[[@CR77]\]. Relapse rates after HBeAg seroconversion as high as 50% have been reported in these patients \[[@CR78]\]. These results suggest that not all patients with HBeAg seroconversion have treatment-free remission after stopping antiviral therapy, especially those among Asian patients.

### HBeAg-negative patients {#Sec15}

Treatment cessation criteria are less clearly defined for HBeAg-negative patients but include propositions that treatment may be stopped if undetectable HBV DNA levels have been established on three separate occasions, with 6-month intervals \[[@CR1]\]. While this is based on studies evaluating treatment duration that suggested that up to 50% of patients have maintained viral suppression following treatment cessation \[[@CR79]--[@CR81]\], the challenge remains in identifying those 50% of patients who would benefit from continued therapy. A study of patients treated with lamivudine for 48 weeks reported similar results, with 73% of patients having HBV DNA levels of \<400 copies/mL upon treatment cessation compared with 7% at the end of 24 weeks follow-up. Eight percent of patients who discontinued 48 weeks' adefovir therapy had HBV DNA levels of \<1,000 copies/mL after 48 weeks' follow-up compared with 71% of patients who continued therapy through 96 weeks \[[@CR82], [@CR83]\]. Consequently, most major guidelines recommend long-term treatment of HBeAg-negative patients or until sustained HBsAg seroclearance has been demonstrated \[[@CR2], [@CR3]\].

### HBsAg seroclearance {#Sec16}

Various studies have shown that patients with spontaneous HBsAg seroclearance have favorable biochemical, virological, and histological parameters, with markedly improved necroinflammation and unchanged or regressed liver fibrosis despite occult HBV infection \[[@CR84], [@CR85]\]. HBsAg seroclearance usually confers favorable outcome if there is no preexisting cirrhosis or viral superinfection, though adverse complications may still occur. Furthermore, HBsAg seroclearance before the age of 50 years is associated with a lower risk of HCC than seroclearance at an older age \[[@CR86]\].

Nonetheless, spontaneous or treatment-induced HBsAg seroclearance has long been considered a rare occurrence. Earlier studies reported the spontaneous annual seroclearance rate in high endemic areas to be as low as 0.1 to 0.8% \[[@CR87]\]. One recent follow-up study, however, reported the cumulative seroclearance rate in asymptomatic HBeAg-negative patients to be 40% after 25 years. It is worth noting that these patients initially had undetectable HBV DNA and normal ALT levels \[[@CR87]\]. The occurrence of HBsAg seroclearance among patients treated with long-term lamivudine is rare \[[@CR88]\]. Among HBeAg-negative patients receiving 5 years of adefovir treatment, approximately 5% achieved HBsAg seroclearance \[[@CR89]\]. For HBeAg-positive patients receiving 1 year of tenofovir treatment \[[@CR72]\] and 2 years of entecavir treatment \[[@CR71]\], HBsAg seroclearance occurred in 3 and 5% of patients, respectively. Adopting HBsAg seroclearance as an end point in these cases means potentially committing all patients to long-term treatment. Further studies are needed to define patient groups that have a high chance of HBsAg seroclearance by antiviral treatment.

To complicate the picture further, the reliability of HBsAg seroclearance as an end point has been questioned. One study has shown that 34% of Asian patients who are HBsAg negative have detectable HBV DNA in the liver despite serum levels being undetectable. Another study reported detectable hepatic HBV DNA in 73% of HBsAg-negative Japanese patients, suggesting that most patients continue to harbor HBV infection \[[@CR90], [@CR91]\]. The long-term safety of nucleos(t)ide analogs is also an important consideration, with the termination of phase III clevudine trials due to myopathy an indication of the danger in relying on 1-year clinical trial safety profiles \[[@CR92]\]. Adefovir and tenofovir can cause nephrotoxicity, and telbivudine is associated with myopathy and neuropathy \[[@CR93], [@CR94]\]. There are no serious reports of lamivudine- and entecavir-related toxicity, but further long-term studies are needed \[[@CR92]\].

### Treatment reinitiation {#Sec17}

Defined treatment reinitiation criteria are not mentioned in current CHB management guidelines. Moreover, current re-treatment data are limited. Lamivudine re-treatment studies have involved small patient cohorts (30--60 patients) manifesting high rates of drug resistance due to lamivudine's low genetic barrier and intermediate potency \[[@CR95]\]. Recent studies on entecavir re-treatment appear more promising, as undetectable HBV DNA levels (\<300 copies/mL) have been reported in 95% of HBeAg-negative patients 3 years following treatment reinitiation \[[@CR96]\].

APPROACH Working Group consensus {#Sec18}
--------------------------------

Treatment cessation criteria and clinical treatment end points are difficult to define, and the best treatment end point associated with the lowest risk of relapse remains unclear.

The short-term target of antiviral therapy is currently defined in many guidelines as maintained suppression of HBV replication, with or without HBeAg seroconversion \[[@CR1], [@CR12]\]. To avoid disease progression and to minimize the risk of resistance, maintained viral suppression is important, particularly in HBeAg-negative and HBeAg-positive patients who have not yet achieved HBeAg seroconversion. For seroconverted patients, recent data have demonstrated that HBeAg seroconversion alone may not signify freedom from risk of disease progression and hepatitis relapse is common after treatment cessation \[[@CR40], [@CR76], [@CR77]\]. Current evidence suggests that HBsAg seroclearance would be a preferred end point. In line with recent EASL updates, existing guidelines need to be revised to include sustainable suppression of HBV replication, *with HBsAg seroclearance* as the preferred treatment end point; however, only a small proportion of patients can achieve this end point with currently available oral nucleos(t)ide analogs.

Studies have suggested that serial measurements of HBsAg concentration (titer) may be useful in determining the ideal treatment end point \[[@CR97]\], and the quantitation of HBsAg may reflect the amount of covalently, closed, circular DNA inside the hepatocyte \[[@CR98]\]. Future studies in this area are of interest.

As the timing of treatment initiation may determine the timing of HBsAg seroclearance \[[@CR86]\], and ultimately affect disease progression, the adoption of a preventative approach to CHB treatment, identifying patients at risk using thorough pretreatment evaluation criteria and initiating treatment as early as possible, is strongly advocated.

Patient monitoring should continue to be mandatory upon treatment cessation. While a recent study suggested reinitiation of therapy is effective \[[@CR96]\], data remain limited and re-treatment criteria should be the same as those for treatment initiation, as indicated in current APASL or American Association for the Study of Liver Diseases guidelines.

Finally, sustained HBeAg seroconversion may remain an appropriate treatment goal for some patients, for example, young HBeAg-positive patients without advanced disease. As indicated in current guidelines, 6--12 months of consolidation therapy and monitoring for relapse are crucial upon treatment cessation in these patients \[[@CR1]--[@CR3]\]. Determining the risk of disease progression and HCC development in these patients through employment of a "risk calculator" may help answer the crucial questions of "whom to treat" and "for how long"?

Summary {#Sec100}
=======

Current challenges and considerations for future guidelines amendments on "whom to treat" (Table [1](#Tab1){ref-type="table"}) and "for how long" (Table [2](#Tab2){ref-type="table"}) are summarized below.Table 1Treatment initiation: whom to treat?*Current challenges*Current, stringent treatment initiation criteria may exclude HBV-infected patients at high risk of HCC from treatmentRoutine invasive liver biopsy poses clinical limitations, with variable validity as well as potential patient compliance issues; alternative noninvasive means of assessing liver fibrosis are required*APPROACH consensus*Symptomatic patients must be treated as early as possibleFor asymptomatic patients refusing liver biopsy, noninvasive fibrosis assessment should be considered and appropriate risk prediction/calculation completedNoninvasive fibrosis assessments should be further studied for routine use, instead of liver biopsy, before decisions are made to initiate or cease treatmentAn improved treatment assessment algorithm or risk calculator, incorporating all HCC risk factors and common liver parameters, is required to aid hepatologists in redefining treatment initiation criteriaTable 2Treatment cessation: for how long?*Current challenges*Existing treatment end points have not been demonstrated to sufficiently prevent reactivation or disease progressionAchieving treatment goals and defining appropriate clinical treatment end points are often difficultTreatment end points are constantly evolving as the understanding of CHB natural history and factors associated with disease progression improves*APPROACH consensus*HBsAg seroclearance is currently the single preferred treatment end point for inclusion in future recommendations and more research is required to determine its likelihood in specific patient populationsHBeAg seroconversion may continue to be an appropriate end point accompanied by undetectable HBV DNA for certain patients with a low, predetermined risk of HCC developmentThe duration of consolidated treatment after HBeAg seroconversion requires further study with newer antiviral agents, and routine patient monitoring for relapse should remain mandatory upon treatment cessation in all CHB patients

Bristol-Myers Squibb provided an unrestricted educational grant to accredited medical education provider, Adrenalin Strategics (Australia), for management of the APPROACH Working Group meeting. Editorial support for the development of this report was provided by Adrenalin Strategics (Australia) and MediTech Media (Singapore).

**Conflict of interest statement** Sang Hoon Ahn has received research support from Bristol-Myers Squibb and has acted as an advisor and lecturer for Bristol-Myers Squibb, GlaxoSmithKline, and Novartis Pharmaceuticals.Henry L. Y. Chan has served on the Advisory Board of Bristol-Myers Squibb, Novartis Pharmaceuticals, Pharmasset, and Schering Plough Pharmaceuticals.Jinlin Hou has served on the Advisory Board of Bristol-Myers Squibb and Novartis Pharmaceuticals and is on the speaker's bureau for GlaxoSmithKline, Novartis Pharmaceuticals, and Bristol-Myers Pharmaceuticals.Seng Gee Lim has served on the Advisory Board of Bristol-Myers Squibb, Novartis Pharmaceuticals, and Schering Plough Pharmaceuticals and is on the speaker's bureau for GlaxoSmithKline, Novartis Pharmaceuticals, and Bristol-Myers Pharmaceuticals.Masao Omata has served on the Advisory Board of Bristol-Myers Squibb, Pfizer, and Roche and is on the consulting board for Boehringer Ingelheim, Merck, and Taiho Pharmaceutical.Teerha Piratvisuth has served on the Advisory Board of Novartis Pharmaceuticals, Roche, GlaxoSmithKline, and Schering Plough Pharmaceuticals.Man-Fung Yuen has served on the Advisory Board of Bristol-Myers Squibb and GlaxoSmithKline and is on the speaker\'s bureau for GlaxoSmithKline, Bristol-Myers Pharmaceuticals, and Roche Diagnostics.
